Galmed Pharma (GLMD) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. MRK
8. LVS
9. CSX
10. LRCX

Go back to Galmed Pharma (GLMD) Tops Q2 EPS by 4c

Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America, and Reports Second Quarter 2015 Financial Results

August 13, 2015 7:47 AM EDT

TEL AVIV, Israel, Aug. 13, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it has commenced patient screening for the ARREST Study in the United States and Latin America, as well as reported financial results for the three and six months ended June 30, 2015.

Financial Summary Second Quarter 2015 vs. Second Quarter 2014:

Net loss of $2.4 million, or $0.21 per share, for the three months ended June 30, 2015,... More